Source link : https://www.newshealth.biz/health-news/measuring-expectations-real-world-survival-with-osimertinib/
Over the past few years, osimertinib has received much fanfare among lung cancer experts. Results from the phase 3 LAURA trial were met with a standing ovation at the 2024 American Society of Clinical Oncology annual meeting, after the trial demonstrated a 33.5-month progression-free survival benefit in patients with EGFR-mutated unresectable stage 3 non–small cell lung […]
Author : News Health
Publish date : 2024-08-28 11:32:48
Copyright for syndicated content belongs to the linked Source.
Categories